We help our customers to deal with challenging recombinant proteins related projects. To see some solved ones, please provide us with your name and email address. We will be happy to send you selected case studies presentation showcasing our competences. Maybe issues you are facing now, are already described there...
PureSelect (antibody phage display)
A human recombinant monoclonal antibody selection platform against custom molecular targets, including whole cells. Currently, most antibodies used in biomedical research and biotherapeutic applications are obtained by in vivo immunization of animals and subsequent selection utilizing hybridoma screening technology. The antibodies obtained in this way need to be further ‘humanized’ in order to be safely used in clinical studies.
Our proprietary technology allows for in vitro selection of high-affinity human recombinant antibodies against practically any custom antigen, including whole-cell immunization, without the need for subsequent humanization. Following the primary selection of interacting clones, an affinity maturation library can be constructed to further enhance antigen-binding affinity. Finally, the selected antibody fragments can be converted (using recombinant DNA technology) into the other antibody formats, including: full IgG molecule, Fab or scFv dimer, and further chemically functionalized to give rise to a drug lead candidate, for example, an antibody drug conjugate (ADC), or molecular diagnostic tool, such as a fluorescent labeled probe.